Summary
Ten patients (mean age 53 years) with essential hypertension have been studied at rest and during exercise following oral treatment for 6 weeks with a new beta-adrenoceptor blocking agent, bopindolol.
The treatment caused a significant decrease in systolic and diastolic arterial blood pressure and heart rate, both at rest and during exercise. Stroke volume fell, too, and therefore so did cardiac output, whereas the systemic vascular resistance was increased. Left ventricular filling pressure was elevated both at rest and during exercise following bopindolol therapy.
However, a different haemodynamic pattern was noted in patients with elevated total peripheral resistance prior to therapy (Group 1) compared to patients with normal or subnormal peripheral resistance (Group 2). A decrease in systemic vascular resistance seemed to be the cause of the fall in blood pressure in Group 1, as the expected increase in vascular resistance did not occur, whereas a reduction in cardiac output was of greater importance in Group 2. During exercise the lowering of arterial blood pressure in both groups was mediated by a reduction in cardiac output.
This is a preview of subscription content, log in via an institution to check access.
References
Aellig WH (1982) Clinical pharmacological experiments with bopindolol (LT 31-200): A long acting β-adrenoceptor blocking drug with partial agonist activity. Br J Clin Pharmacol 13: 267P-268P
Andersson OK, Hedner T, Nyberg G (1985) Acute and long-term antihypertensive effect of bopindolol — a nonselective β-adrenergic blocker with ISA. Eur J Clin Pharmacol 29: 281–285
Bello CT, Sevy RW, Harakal C, Hillyer PN (1967) Relationship between clinical severity of disease and hemodynamic patterns in essential hypertension. Am J Med Sci 253: 194–208
Berthold R, Waite R, Weber H (1981) Pharmacological studies with bopindolol: a new long acting β-adrenoceptor antagonist. Br J Pharmacol 74: 829P
Van Brummelen P, Bühler FR, Amann FW, Bolli P (1982) Effects of a new long-acting beta-blocker bopindolol (LT 31-200) on blood pressure, plasma catecholamines, renin and cholesterol in patients with arterial hypertension. Eur J Clin Pharmacol 22: 491–493
Van Brummelen P, Bolli P, Koolen MI, Staehelin HB, Bühler FR (1984) Plasma lipid fractions during long-term monotherapy with the ISA-containing β-adrenoceptor blocker bopindolol in hypertensive patients. Br J Clin Pharmacol 17: 86–88
Falicov RE, Resnekov L (1970) Relationship of the pulmonary artery end-diastolic pressure of the left ventricular end-diastolic and mean filling pressures in patients with and without left ventricular dysfunction. Circulation 42: 65–72
Fitscha P, Meisner W, Tiso B (1986) Influence of atenolol and bopindolol on circadiane heart rate. J Cardiovasc Pharmacol 8 [Suppl 6]: 51–54
Hulthen UL, van Brummelen P, Amann FW, Bühler FR (1983) Antihypertensive efficacy of the new long-acting β-blocker bopindolol as related to age. J Cardiovasc Pharmacol 5: 426–429
Johnsson G (1975) Influence of metoprolol and propranolol on haemodynamic effects induced by adrenaline and physical work. Acta Pharmacol Toxicol 36 [Suppl V]: 59–68
Kumaroto K, Murata K, Yazaki Y, Ikeda M, Nakao K (1968) Haemodynamics in early essential hypertension with special reference to the response to propranolol. Japn Circ J 32: 981–987
Nyberg G (1985) Intrinsic sympathomimetic activity of bopindolol, a non-selective β-adrenoceptor antagonist. Br J Clin Pharmacol 20: 242P-243P
Sannerstedt R (1966) Haemodynamic response to exercise in patients with arterial hypertension. Acta Med Scand 180 [Suppl 458]: 1–83
Schiess W, Welzel D, Gugler R (1984) Double-blind comparison of once-daily bopindolol, pindolol and atenolol in essential hypertension. Eur J Clin Pharmacol 27: 529–534
Turner DR, Goodwin FJ, Knight AR, Littlejohns DW, Sharman VL, Vere DW (1984) Bopindolol: A new long acting β-receptor antagonist; its effects on hemodynamics and on the renin response to tilting. Br J Clin Pharmacol 17: 295–299
Varnauskas E (1955) Studies in hypertensive cardiovascular disease with special reference to cardiac function. Scand J Clin Lab Invest 7 [Suppl 17]: 1–117
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Fitscha, P., Meisner, W., Brandstetter, G. et al. Haemodynamic effects of short-term treatment with bopindolol in essential hypertension. Eur J Clin Pharmacol 34, 411–413 (1988). https://doi.org/10.1007/BF00542445
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00542445